Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: -7.50 (-8.33%)
Spread: 5.00 (6.25%)
Open: 90.00
High: 90.00
Low: 82.50
Prev. Close: 90.00
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Annual General Meeting - Amendment

6 Nov 2020 15:03

RNS Number : 5643E
Feedback PLC
06 November 2020
 

 

The following amendments have been made to the 'Result of Annual General Meeting' announcement released on 5 November 2020 at 1.23 pm under RNS No 4187E.

 

The 'Total Votes Cast' column in the table below has been updated to show the correct figures. All other details remain unchanged. The full amended text is shown below.

 

Feedback plc

 

Result of Annual General Meeting - Amendment

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that at its annual general meeting held earlier today, all resolutions were duly passed on a poll. The proxy voting results of the resolutions are included below.

 

 

Resolutions

Votes For*

% of votes cast**

Votes Against

% of votes cast**

Votes Withheld**

Total votes cast**

1. To receive and adopt the annual report and accounts for the year ended 31 May 2020

504,134,927

100.00%

-

0.00%

22,000

504,134,927

2. To elect Adam Denning as a director

504,152,622

100.00%

3,305

0.00%

1,000

504,155,927

3. To elect Philipp Prince as a director

479,902,622

95.19%

24,253,305

4.81%

1,000

504,155,927

4. To re-elect Simon Sturge as a director

504,152,486

100.00%

3,441

0.00%

1,000

504,155,927

5. To appoint Price Bailey LLP as auditors of the Company

504,118,963

99.99%

36,964

0.01%

1,000

504,155,927

6. To authorise the directors to allot relevant securities equivalent to up to two thirds of the Company's issued share capital, subject to certain conditions

504,027,372

100.00%

3,305

0.00%

126,250

504,030,677

7. To authorise the directors to allot relevant securities equivalent to up to 10 per cent. of the Company's issued share capital on a non-pre-emptive basis subject to certain conditions

478,945,731

95.01%

25,135,091

4.99%

76,205

504,080,822

 

Notes:

* "Votes For" include votes giving the Chairman discretion.

** "Votes Withheld" are not votes in law and do not count in the number of votes counted for or against a resolution, or towards the total votes cast.

 

-Ends-

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGZMGMKVGGGZM
Date   Source Headline
1st Oct 20187:00 amRNSAppointment of Joint Broker
10th Sep 20187:00 amRNSTexRAD® ordered by Samsung Medical Centre in Seoul
17th Aug 20182:02 pmRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSFirst GE Healthcare order for TexRAD®
1st Aug 20181:19 pmRNSDirector/PDMR Shareholding
20th Jul 20187:00 amRNSDirectorate Change
6th Jul 20187:00 amRNSJoint broker update
29th Jun 20183:20 pmRNSDirector/PDMR Shareholding
27th Jun 20187:00 amRNSGrant of Options and Director/PDMR Dealing
22nd Jun 20182:10 pmRNSResult of General Meeting
8th Jun 201810:36 amRNSHolding(s) in Company
7th Jun 20187:05 amRNSNotice of General Meeting
7th Jun 20187:00 amRNSRevised strategy to build a global company
1st Jun 20187:00 amRNSAppointment of new Medical Director
10th May 20189:27 amRNSHolding(s) in Company
4th May 20186:09 pmRNSHolding(s) in Company
1st May 20187:00 amRNSDirector/PDMR Shareholding
30th Apr 20185:00 pmRNSTotal Voting Rights
27th Apr 20187:00 amRNSTwo-year contract with Royal Papworth Hospital
25th Apr 20182:05 pmRNSSecond Price Monitoring Extn
25th Apr 20182:00 pmRNSPrice Monitoring Extension
25th Apr 20187:00 amRNSDistribution agreement with GE Healthcare
17th Apr 20187:00 amRNSHolding(s) in Company
16th Apr 20187:30 amRNSNew Company Structure and Directorate Change
16th Apr 20187:25 amRNSAppointment of non-executive director
9th Apr 20182:39 pmRNSHolding(s) in Company
29th Mar 20187:00 amRNSEquity Fundraising to raise £440,000
21st Mar 20189:01 amRNSHolding(s) in Company
16th Mar 20185:11 pmRNSHolding(s) in Company
16th Mar 20187:00 amRNSDirectorate Change
8th Mar 20188:48 amRNSHolding(s) in Company
7th Mar 20182:39 pmRNSHolding(s) in Company
1st Mar 20181:03 pmRNSHolding(s) in Company
26th Feb 20187:00 amRNSHalf-year Report
14th Feb 20187:00 amRNSDirectorate Change
9th Feb 201812:04 pmRNSHolding(s) in Company
5th Feb 20181:56 pmRNSHolding(s) in Company
28th Dec 20175:42 pmRNSHolding(s) in Company
28th Dec 20175:19 pmRNSTotal Voting Rights
20th Dec 20179:33 amRNSHolding(s) in Company
30th Nov 20174:38 pmRNSResult of AGM
22nd Nov 20179:37 amRNSHolding(s) in Company
22nd Nov 20177:00 amRNSPresentation at RSNA 2017
20th Nov 201712:40 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSFirst CE marked release of TexRAD® technology
7th Nov 20177:00 amRNSFinal Results
14th Sep 20177:00 amRNSHolding(s) in Company
31st Jul 20175:00 pmRNSTotal Voting Rights
28th Jul 201710:53 amRNSCCI Exclusive Distributor agreement with Boya
30th Jun 20172:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.